## Electronic Supplementary Material

## Direct detection of illicit drugs from biological fluids by desorption/ionization mass spectrometry with nanoporous silicon microparticles

T.M. Guinan<sup>a</sup>, P. Kirkbride<sup>b</sup>, C. B. Della Vedova<sup>c</sup>, S. G. Kershaw<sup>c</sup>, H. Kobus<sup>b</sup> and N. H. Voelcker<sup>a</sup>

<sup>a</sup>ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Mawson Institute, Australia

<sup>b</sup>School of Physical and Chemical Sciences, Flinders University, Bedford Park, SA 5042, Australia

<sup>c</sup>School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia

Corresponding author: Nicolas H. Voelcker\* ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Mawson Insititute, University of South Australia GPO Box 2471, Adelaide SA 5001, Australia Phone: +61 (08) 8302 5508 Fax: +61 (08) 8302 5613 E-mail: <u>nico.voelcker@unisa.edu.au</u>

## Material and methods

Determination of Plasma Oxycodone and Metabolite Concentration via SPE-LC-MS-MS: Plasma oxycodone and metabolite concentrations were analyzed from liquid chromatography mass spectrometry (LC-MS) using a a Shimadzu Nexera LC-30AD UHPLC system and an AB Sciex 5600 TripleTOF<sup>™</sup> mass spectrometer. Chromatographic separation was performed using a Phenomenex Gemini pentafluorophenyl C18 column (5 um, 100 A, 250 x 4.6 mm). AFCV-32AH switching valve (Shimadzu Corp., Japan) was employed to divert only the LC eluent between 5 and 9 min to mass spectrometer to protect it from potential contamination. The mass spectrometer was operated in positive ion mode. The m/z 316/298 ion was monitored for oxycodone, the m/z 302/284 for oxymorphone and noroxycodone and the m/z 305/287 for noroxycodone-d3, respectively.



**Fig. S1.** A) DRIFT-IR spectra of oxidized,  $F_5$ Ph,  $F_{13}$  and ODS functionalized pSi-MPs. B) Inset of (A) showing the fingerprint region between 1700 and 500 cm<sup>-1</sup>.



**Fig. S2.** SEM micrographs of pSi-MPs etched at A) 55 mA/cm<sup>2</sup>, 4 min, B) 111 mA/cm<sup>2</sup>, 2 min, C) 111 mA/cm<sup>2</sup>, 4 min, D) 111 mA/cm<sup>2</sup>, 6 min, E) 222 mA/cm<sup>2</sup>, 2 min, F) 222 mA/cm<sup>2</sup>, 4 min and G) 333 mA/cm<sup>2</sup>, 4 min. Scale bar is 300 nm. Graphs representing average pore size (H) and thickness (I) for n=20 replicates.



**Fig. S3.** SEM micrographs of sieved pSi-MPs using 25, 53 and 75  $\mu$ m sieves, respectively. Sieving produced pSi-MPs with particle sizes of A) 19.2 ± 2.4  $\mu$ m, B) 35.2 ± 7.2  $\mu$ m, C) 56.1 ± 8.3  $\mu$ m and D) 85.0 ± 17.2  $\mu$ m.

Cocaine (1000 ng/mL)	85.0 ± 17.2 μm	35.2 ± 7.2 μm	19.2 ± 2.4 μm
85.0 ± 17.2 μm	P<.01	P<.05	P<.01
56.1 μm± 8.3 μm		P<.01	P<.01
35.2 ± 7.2 μm			P<.01
MDMA (1000 ng/mL)	85.0 ± 17.2 μm	35.2 ± 7.2 μm	19.2 ± 2.4 μm
85.0±17.2 μm	n/s	P<.05	P<.01
56.1 μm± 8.3 μm		P<.01	P<.01
35.2 ± 7.2 μm			P<.01
Methadone (1000 ng/mL)	85.0 ± 17.2 μm	35.2 ± 7.2 μm	19.2 ± 2.4 μm
85.0 ± 17.2 μm	n/s	n/s	P<.01
56.1 μm± 8.3 μm		n/s	P<.01
35.2 ± 7.2 μm			P<.01

 Table S1. Turkey HSD Test for post ANOVA pair-wise comparisons in a one way ANOVA.



Fig. S4. SALDI mass spectra for cocaine on A) 85.0  $\pm$  17.2  $\mu$ m, B) 56.1  $\pm$  8.3  $\mu$ m, C) 35.2  $\pm$  7.2  $\mu$ m and D) 19.2  $\pm$  2.4  $\mu$ m pSi-MPs functionalized with F<sub>13</sub>.



**Fig. S5.** Full width half maximum (FWHM) values for sieved pSi-MPs corresponding to average S/N observed for the detection of cocaine on  $19.2 \pm 2.4 \mu m$ ,  $35.2 \pm 7.2 \mu m$ ,  $56.1 \pm 8.3 \mu m$  and  $85.0 \pm 17.2 \mu m$ . FWHM was calculated using flexAnalysis software. Error bars correspond to standard deviation (n=3).



**Fig. S6.** Representative SALDI-MS/MS spectrum observed for cocaine in water. Characteristic fragment peaks were observed at m/z 272 and 182.



**Fig. S7.** Representative SALDI mass spectrum observed for a urine sample analyzed on  $F_{13}$  functionalized pSi-MP showing the presence of EDDP (MH<sup>+</sup> 278).



**Fig. S8.** SALDI mass spectra on  $F_{13}$  functionalized pSi-MP for oxycodone in A) plasma (20.4 ng/mL) and B) saliva 2 h post dose. Star represents the detection of oxycodone (MH<sup>+</sup> 316).